blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3601581

EP3601581 - CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  15.08.2024
Database last updated on 18.11.2024
FormerRequest for examination was made
Status updated on  03.01.2020
FormerThe international publication has been made
Status updated on  29.09.2018
Most recent event   Tooltip18.10.2024New entry: Reply to examination report 
Applicant(s)For all designated states
Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato, CA 94949 / US
[2020/06]
Inventor(s)01 / TIERNAN, Aubrey
16 Powder House Terrace
Somerville, MA 02474 / US
02 / TIPPER, Christopher
6 Thingvalla Ave.
Cambridge, MA 02138 / US
 [2020/06]
Representative(s)Haseltine Lake Kempner LLP
Cheapside House
138 Cheapside
London EC2V 6BJ / GB
[N/P]
Former [2020/06]Haseltine Lake Kempner LLP
Lincoln House, 5th Floor
300 High Holborn
London WC1V 7JH / GB
Application number, filing date18771556.022.03.2018
[2020/06]
WO2018US23841
Priority number, dateUS201762475112P22.03.2017         Original published format: US 201762475112 P
[2020/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018175775
Date:27.09.2018
Language:EN
[2018/39]
Type: A1 Application with search report 
No.:EP3601581
Date:05.02.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 27.09.2018 takes the place of the publication of the European patent application.
[2020/06]
Search report(s)International search report - published on:US27.09.2018
(Supplementary) European search report - dispatched on:EP20.04.2021
ClassificationIPC:C12N15/86, A61K48/00, C12N7/00
[2020/06]
CPC:
C12N15/86 (EP,US); C12N7/00 (US); C12N2330/51 (US);
C12N2510/02 (US); C12N2511/00 (US); C12N2750/14122 (EP,US);
C12N2750/14143 (EP,US); C12N2750/14152 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/06]
TitleGerman:ZELLKULTURVERFAHREN MIT HDAC-HEMMERN ODER REP-PROTEINEN[2020/06]
English:CELL CULTURE METHODS INVOLVING HDAC INHIBITORS OR REP PROTEINS[2020/06]
French:PROCÉDÉS DE CULTURE CELLULAIRE FAISANT INTERVENIR DES INHIBITEURS DE HDAC OU DES PROTÉINES REP[2020/06]
Entry into regional phase10.10.2019National basic fee paid 
10.10.2019Search fee paid 
10.10.2019Designation fee(s) paid 
10.10.2019Examination fee paid 
Examination procedure10.10.2019Examination requested  [2020/06]
22.11.2021Amendment by applicant (claims and/or description)
16.08.2024Despatch of a communication from the examining division (Time limit: M04)
16.10.2024Reply to a communication from the examining division
Fees paidRenewal fee
27.03.2020Renewal fee patent year 03
29.03.2021Renewal fee patent year 04
28.03.2022Renewal fee patent year 05
08.03.2023Renewal fee patent year 06
19.03.2024Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2014201252  (SHIRE HUMAN GENETIC THERAPIES [US]);
International search[XY]US2002115189  (NATSOULIS GEORGES [US], et al);
 [Y]US2011251547  (XING JAMES [CA], et al);
 [Y]US2012058917  (GAKEN JOHANNES ADRIANUS [GB], et al);
 [XY]US2014359799  (WANG ZHENGNE [US], et al);
by applicantUS5387484
 WO9617947
 US5688676
 US5691176
 US5741683
 WO0024916
 WO0047757
 US6156303
 US2002081721
 US8163543
 WO2014201252
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.